1999
CD95 ligand expression in dedifferentiated breast cancer
Müschen M, Moers C, Warskulat U, Niederacher D, Betz B, Even J, Lim A, Josien R, Beckmann M, Häussinger D. CD95 ligand expression in dedifferentiated breast cancer. The Journal Of Pathology 1999, 189: 378-386. PMID: 10547600, DOI: 10.1002/(sici)1096-9896(199911)189:3<378::aid-path439>3.0.co;2-d.Peer-Reviewed Original ResearchConceptsReverse transcriptase-polymerase chain reactionBreast cancerCD95 ligand expressionMRNA levelsLigand expressionGrade III breast cancerMammary tissueCD95L mRNA levelsTumor-infiltrating lymphocytesCD95 ligandHigh-grade carcinomaQuantitative reverse transcriptase-polymerase chain reactionBenign mammary tissuesTissue sectionsBreast cancer tissuesNon-malignant mammary tissuesTranscriptase-polymerase chain reactionBreast cancer tissue sectionsBreast cancer sectionsCancer tissue sectionsGrade IGrade IIHistopathological gradingReceptor expressionCancer tissuesInvolvement of Soluble CD95 in Churg-Strauss Syndrome
Müschen M, Warskulat U, Perniok A, Even J, Moers C, Kismet B, Temizkan N, Simon D, Schneider M, Häussinger D. Involvement of Soluble CD95 in Churg-Strauss Syndrome. American Journal Of Pathology 1999, 155: 915-925. PMID: 10487849, PMCID: PMC1866905, DOI: 10.1016/s0002-9440(10)65191-7.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedApoptosisCell SurvivalCells, CulturedChurg-Strauss SyndromeClone CellsCulture Media, ConditionedEnzyme-Linked Immunosorbent AssayEosinophilsFas Ligand ProteinFas ReceptorFemaleGenes, T-Cell Receptor betaHumansImmunosuppressive AgentsMaleMembrane GlycoproteinsMiddle AgedMultigene FamilyReceptors, Tumor Necrosis FactorReverse Transcriptase Polymerase Chain ReactionRNA, MessengerT-LymphocytesConceptsChurg-Strauss syndromeSoluble CD95CSS patientsOligoclonal T cell expansionTCR Vbeta gene usageAutoimmune lymphoproliferative disordersVbeta gene usageRole of eosinophilsT cell expansionPeripheral blood lymphocytesT cell clonesSoluble splice variantCD95L-mediated apoptosisCD95 receptor expressionImmunosuppressive therapyClinical improvementCDR3 motifsEffector cellsLymphoproliferative disordersCS patientsBlood lymphocytesReceptor expressionHealthy individualsVbeta genesEosinophilsRegulation of CD95 (APO‐1/ FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin
Moers C, Warskulat U, Müschen M, Even J, Niederacher D, Josien R, Koldovsky U, Beckmann M, Häussinger D. Regulation of CD95 (APO‐1/ FAS) ligand and receptor expression in squamous‐cell carcinoma by interferon‐γ and cisplatin. International Journal Of Cancer 1999, 80: 564-572. PMID: 9935158, DOI: 10.1002/(sici)1097-0215(19990209)80:4<564::aid-ijc14>3.0.co;2-x.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaExpression of CD95LPrimary cell linesPrimary squamous cell carcinomaStroma cellsCD95L expressionAddition of CDDPCD95L mRNA levelsTumor-associated immunosuppressionHuman primary cell linesMRNA levelsEffect of cisplatinCell linesCD95 ligand expressionInvasive tumor tissuesAutologous lymphocytesCell carcinomaReceptor expressionSCC cellsSoluble receptorLigand expressionTumor tissueTumor samplesReceptor isoformsInvasion factors
1998
Regulation of CD95 (Apo-1/Fas) Ligand and Receptor Expression in Human Embryonal Carcinoma Cells by Interferon γ and all-trans Retinoic Acid
Müschen M, Warskulat U, Schmidt B, Schulz W, Häussinger D. Regulation of CD95 (Apo-1/Fas) Ligand and Receptor Expression in Human Embryonal Carcinoma Cells by Interferon γ and all-trans Retinoic Acid. Biological Chemistry 1998, 379: 1083-1092. PMID: 9792441, DOI: 10.1515/bchm.1998.379.8-9.1083.Peer-Reviewed Original ResearchConceptsTrans retinoic acidTera-2 cellsTera-2 embryonal carcinoma cellsEmbryonal carcinoma cellsRetinoic acidT lymphocytesCarcinoma cellsJurkat T lymphocytesCD95 ligandReceptor isoformsCD95 receptorCD95 ligand expressionHuman embryonal carcinoma cellsAntitumor immunityControl conditionReceptor expressionInterferon γInterferon gammaLigand expressionProtein levelsDifferential regulationCD95 ligationIFNgammaLymphocytesApoptosis